| scholarly article | Q13442814 |
| P50 | author | Vera Ehrenstein | Q55232647 |
| Sinna Pilgaard Ulrichsen | Q83391828 | ||
| Javier Cid Ruzafa | Q85212473 | ||
| P2093 | author name string | Dimitri Bennett | |
| P2860 | cites work | Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales | Q39376180 |
| Pioglitazone and bladder cancer: FDA's assessment | Q40389639 | ||
| The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis | Q46132812 | ||
| Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus | Q46743528 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| The Danish Civil Registration System. | Q50554185 | ||
| The Danish National Patient Register. | Q50554196 | ||
| Publication bias in epidemiological studies. | Q53086474 | ||
| Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin | Q85197540 | ||
| What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes | Q85215123 | ||
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| The Danish National Patient Registry: a review of content, data quality, and research potential | Q26775834 | ||
| The Danish Adult Diabetes Registry | Q28077944 | ||
| Comparison of the Five Danish Regions Regarding Demographic Characteristics, Healthcare Utilization, and Medication Use--A Descriptive Cross-Sectional Study | Q28606751 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions | Q30579857 | ||
| Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). | Q31120403 | ||
| Publication bias in meta-analysis: its causes and consequences | Q33870662 | ||
| Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark | Q33870957 | ||
| Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 | ||
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 | ||
| Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study | Q34592900 | ||
| Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. | Q34671802 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 | ||
| Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries | Q37179822 | ||
| Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014. | Q37354252 | ||
| Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis | Q37576689 | ||
| The Danish Civil Registration System as a tool in epidemiology | Q38223251 | ||
| Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis | Q38417421 | ||
| Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue | Q38652782 | ||
| Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis | Q38721611 | ||
| Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study. | Q38880114 | ||
| P433 | issue | 3 | |
| P921 | main subject | Denmark | Q35 |
| P304 | page(s) | 133-140 | |
| P577 | publication date | 2019-09-01 | |
| P1433 | published in | Drugs - real world outcomes | Q27726504 |
| P1476 | title | Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication | |
| P478 | volume | 6 |
Search more.